| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/21/2002 | WO2002014368A2 Proteins and nucleic acids encoding the same |
| 02/21/2002 | WO2002014367A1 Chimeric human-type vascular endothelial cell growth factor |
| 02/21/2002 | WO2002014366A2 Genes involved in immune related responses observed with asthma |
| 02/21/2002 | WO2002014365A1 A new polypeptide-ras gtp activator protein 12 and the polynucleotide encoding it |
| 02/21/2002 | WO2002014364A2 Rattlesnake venom gland proteins |
| 02/21/2002 | WO2002014362A2 A hepatitis c virus non-structural ns3/4a fusion gene |
| 02/21/2002 | WO2002014360A1 Integrin binding motif containing peptides and methods of treating skeletal diseases |
| 02/21/2002 | WO2002014359A2 Human serpin zserp15 |
| 02/21/2002 | WO2002014358A2 Novel secreted proteins and their uses |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014354A1 Water soluble thiazolyl peptide derivatives |
| 02/21/2002 | WO2002014353A1 Anti-heparin peptides |
| 02/21/2002 | WO2002014352A2 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | WO2002014351A2 α7 NICOTINIC RECEPTOR PEPTIDES AS LIGANDS FOR β AMYLOID P EPTIDES |
| 02/21/2002 | WO2002014350A2 Peptide and peptide mimetic derivatives with integrin inhibitor properties ii |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014348A2 Glycoproteins and methods of use thereof |
| 02/21/2002 | WO2002014347A2 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts |
| 02/21/2002 | WO2002014346A2 Antimicrobial peptides isolated from fish |
| 02/21/2002 | WO2002014345A2 Antimicrobial peptides isolated from mast cells |
| 02/21/2002 | WO2002013875A2 Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof |
| 02/21/2002 | WO2002013873A2 P97-active agent conjugates and their methods of use |
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013867A2 Augmented cognitive training |
| 02/21/2002 | WO2002013866A2 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | WO2002013865A1 Agents for ameliorating symptoms caused by joint diseases |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013854A1 Obesity controlling method |
| 02/21/2002 | WO2002013853A1 Skin wound healing promoters |
| 02/21/2002 | WO2002013852A1 Vascular relaxation agents |
| 02/21/2002 | WO2002013851A1 Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neural cell differentiation |
| 02/21/2002 | WO2002013850A1 Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators |
| 02/21/2002 | WO2002013849A1 Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
| 02/21/2002 | WO2002013847A2 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 02/21/2002 | WO2002013846A2 Antifungal combination therapy |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013844A2 Specific autoimmune reactions against isomerised/optically inverted epitopes: application for treatment of autoimmune diseases |
| 02/21/2002 | WO2002013843A2 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013808A2 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | WO2002013799A2 Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013782A1 Oral delivery of peptide |
| 02/21/2002 | WO2002013775A1 Dental products comprising bone growth enhancing peptide |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2002013760A2 Methods and compositions for the repair and/or regeneration of damaged myocardium |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001094530A3 A novel polypeptide, a scan zinc-finger protein subfamily protein 57 and the polynucleotide encoding the polypeptide |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083722A3 Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001082943A3 Subcutaneous administration of coagulation factor vii |
| 02/21/2002 | WO2001082863A3 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001077336A3 Acyl-coa dehydrogenase mutant and uses thereof |
| 02/21/2002 | WO2001077329A8 Human twik molecules and uses thereof |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076561A3 Pharmaceutical compositions |
| 02/21/2002 | WO2001075027A3 A new polypeptide-human rna helicase 13 and the polynucleotide encoding it |
| 02/21/2002 | WO2001075006A3 A novel poypeptide, light chain of protein lattice 37 and the polynucleotide encoding the polypeptide |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001068849A8 Human ion channels |
| 02/21/2002 | WO2001068846A3 Transcription activator of the cited family |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066597A3 Inflammation-related gene |
| 02/21/2002 | WO2001064240A3 Methods for promoting production of myelin by schwann cells |
| 02/21/2002 | WO2001062270A3 Method for treating hashimoto's thyroiditis |
| 02/21/2002 | WO2001060856A3 Vmglom gene and its mutations causing disorders with a vascular component |
| 02/21/2002 | WO2001060395A3 Methods of treatment for non-invasive fungus-induced mucositis with cyclohexapeptide antifungal agents |
| 02/21/2002 | WO2001058409A3 Method of reducing aluminum levels in the central nervous system |
| 02/21/2002 | WO2001057213A3 Human bcl-x-like proteins and polynucleotides encoding the same |
| 02/21/2002 | WO2001057082A3 Extraction of growth factors from tissue |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001056602A3 Cd40 ligand adjuvant for respiratory syncytial virus |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001055319A3 Endocrine related nucleic acids, proteins and antibodies |
| 02/21/2002 | WO2001055175A3 Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001052789A3 PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF |
| 02/21/2002 | WO2001051008A3 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 02/21/2002 | WO2001049832A3 Transduction of recombinases for inducible gene targeting |
| 02/21/2002 | WO2001049255A3 Methods and compositions for inhibiting adhesion by microorganisms |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001046232A3 Soluble interleukin-20 receptor |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001043695A3 Peptide constructs for treating autoimmune and related diseases |
| 02/21/2002 | WO2001042225A3 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 02/21/2002 | WO2001039803A3 Interleukin-1 muteins useful as vaccine adjuvants |
| 02/21/2002 | WO2001039722A3 B7-h1, a novel immunoregulatory molecule |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2001023558A3 Human secretory molecules |
| 02/21/2002 | WO2001003719A3 Combination therapy for conditions leading to bone loss |
| 02/21/2002 | WO2000066148A9 Novel proteins |